{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:58:40Z","timestamp":1759334320351,"version":"build-2065373602"},"reference-count":4,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"3","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>Reporte de caso: Paciente masculino de 77 a\u00f1os con antecedente de angioedema facial hace 20 a\u00f1os tras la ingesta de 500 mg de \u00e1cido-acetilsalic\u00edlico (ASA). En 2024 se le realiz\u00f3 angioplastia con colocaci\u00f3n de stent coronario sin aplicaci\u00f3n de ASA. Ingres\u00f3 a urgencias por dolor precordial, realizando coronariograf\u00eda se confirm\u00f3 infarto agudo al miocardio con la necesidad de colocaci\u00f3n y recolocaci\u00f3n de stents. El servicio de hemodinamia recomend\u00f3 triple terapia con clopidogrel, anticoagulante y ASA. Debido al antecedente de reacci\u00f3n adversa, se solicit\u00f3 interconsulta para evaluar tolerancia a ASA. Se decidi\u00f3 realizar un reto-oral\/desensibilizaci\u00f3n. Previo al procedimiento, present\u00f3 flujo espiratorio m\u00e1ximo (PEF) de 450L\/min, signos vitales (SV) normales y 5 puntos en la escala cl\u00ednica (EC). Se administr\u00f3 ASA cada 15 minutos en dosis progresivas de 10 mg, 32 mg, 85 mg y 174 mg, hasta alcanzar 301 mg acumulados, monitorizando el PEF, SV y EC cada 15 min hasta 4 hrs posteriores del inicio sin presentar alteraciones. Al d\u00eda siguiente se administr\u00f3 dosis de carga de 300 mg de ASA previo a cateterismo coronario y posteriormente mantenimiento de 100 mg\/d.\nConclusi\u00f3n: Existen diversos esquemas de desensibilizaci\u00f3n, Khan propone un esquema con intervalos de 90 minutos utilizando dosis de 40.5 mg, 81 mg, 162 mg y 325 mg. En nuestro caso, reducir los intervalos a 15 minutos facilit\u00f3 la desensibilizaci\u00f3n en menor tiempo, lo cual es \u00fatil en urgencias cardiol\u00f3gicas. La desensibilizaci\u00f3n permiti\u00f3 tolerancia a la dosis de carga previo al cardiointervensionismo y dosis de mantenimiento sin presentar reacciones adversas.\nPalabras clave: Reto oral; Desensibilizaci\u00f3n; \u00c1cido acetilsalic\u00edlico.<\/jats:p>","DOI":"10.29262\/ram.v72i3.1519","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T14:22:58Z","timestamp":1759242178000},"page":"230","source":"Crossref","is-referenced-by-count":0,"title":["&lt;b&gt;Desensibilizaci\u00f3n a \u00c1cido Acetilsalic\u00edlico en paciente con patolog\u00eda coronaria &lt;\/b&gt;","&lt;b&gt;Desensitization to Acetylsalicylic Acid in patients with coronary artery disease\u00a0&lt;\/b&gt;"],"prefix":"10.29262","volume":"72","author":[{"given":"Brenda Mariel","family":"Valerdi Zepeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Rivero Yeverino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida In\u00e9s","family":"L\u00f3pez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrystopherson Gengyny","family":"Caballero L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jes\u00fas","family":"R\u00edos L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"62730","doi-asserted-by":"crossref","unstructured":"-D'Netto M, Sofola-James O, Sehanobish E, Divekar R, Jerschow E. During aspirin desensitization, omitting repeated provoking aspirin dose is safe. J Allergy Clin Immunol Pract. 2023;11(3):955-957.","DOI":"10.1016\/j.jaip.2022.11.040"},{"key":"62731","doi-asserted-by":"crossref","unstructured":"-Cheong Z, Tan CYL, Lim CP, Soong JL, Chong CJM, et al. Patient characterization and predictors of aspirin desensitization response. Asia Pac Allergy. 2021;11(2):e20.","DOI":"10.5415\/apallergy.2021.11.e20"},{"key":"62732","doi-asserted-by":"crossref","unstructured":"-Mullur J, Laidlaw TM. Aspirin allergy labeling after desensitization: education, communication, and patient safety. J Allergy Clin Immunol Pract. 2020;8(10):3629-3630","DOI":"10.1016\/j.jaip.2020.06.018"},{"key":"62733","doi-asserted-by":"crossref","unstructured":"-Laidlaw TM. Aspirin-Exacerbated Respiratory Disease. En Khan DA, Banerji A, editores. Drug Allergy Testing. 1\u00aa ed. Filadelfia: Elsevier; 2018: 171-175.","DOI":"10.1016\/B978-0-323-48551-7.00017-1"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1519\/2766","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1519\/2766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T14:23:00Z","timestamp":1759242180000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/1519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":4,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,30]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v72i3.1519","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"type":"electronic","value":"2448-9190"},{"type":"print","value":"0002-5151"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}